专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO1995023596A1 ADHESIVE FREE TOPICAL PHARMACEUTICAL FORMULATIONS 审中-公开
标题翻译：粘合剂免费的局部药物制剂
公开(公告)号：WO1995023596A1
公开(公告)日：1995-09-08
申请号：PCT/EP1995000791
申请日：1995-03-02
申请人： THE BOOTS COMPANY PLC , AGGARWAL, Meena , HAGUE, John, Neville , KHAN, Karrar, Ahmad , SMITH, Alan
发明人： THE BOOTS COMPANY PLC
IPC分类号： A61K09/70
CPC分类号： A61K9/70
摘要： An adhesive-free topical pharmaceutical formulation comprising an absorbent material wherein the absorbent material is impregnated with a pharmaceutical composition comprising a solution of a non-steroidal anti-inflammatory drug in a C2-4 alcohol. Suitably the non-steroidal antiinflammatory drug comprises ibuprofen, S(+)-ibuprofen, flurbiprofen, S(+)-flurbiprofen, R(-)-flurbiprofen, ketoprofen, S(+)-ketoprofen, piroxicam, or naproxen, including pharmaceutically acceptable salts of each and comprises 0.1-25 % by wight of the pharmaceutical composition. The C2-4 alcohol comprises 20-95 % by weight of the pharmaceutical composition. The pharmaceutical composition further comprises 0.01-90 % by weight of a co-solvent selected from propylene glycol, benzyl alcohol, isopropyl palmitate, isopropyl myristate, or polyvinylpyrrolidone. The formulation is preferably in the form of a wipe or a wrap-around. The formulations are useful for the local treatment of pain and inflammation.
摘要翻译：一种不含粘合剂的局部药物制剂，其包含吸收材料，其中吸收材料用包含非甾体抗炎药在C2-4醇中的溶液的药物组合物浸渍。合适地，非甾体抗炎药包括布洛芬，S（+） - 布洛芬，氟比洛芬，S（+） - 氟比洛芬，R（ - ） - 氟比洛芬，酮洛芬，S（+） - 酮洛芬，吡罗昔康或萘普生，包括药学上可接受的各自的盐并且包含0.1-25％的药物组合物。 C2-4醇包含20-95重量％的药物组合物。该药物组合物还包含0.01-90重量％的选自丙二醇，苯甲醇，棕榈酸异丙酯，肉豆蔻酸异丙酯或聚乙烯吡咯烷酮的共溶剂。制剂优选为擦拭物或包裹物的形式。该制剂可用于局部治疗疼痛和炎症。

2. 发明申请

WO1995020953A1 THERAPEUTIC AGENTS CONTAINING THYROID HORMONES 审中-公开
标题翻译：含有THYROID HORMONES的治疗剂
公开(公告)号：WO1995020953A1
公开(公告)日：1995-08-10
申请号：PCT/EP1995000321
申请日：1995-01-30
申请人： THE BOOTS COMPANY PLC , KHAN, Karrar, Ahmad , SMITH, Alan
发明人： THE BOOTS COMPANY PLC
IPC分类号： A61K31/195
CPC分类号： A61K9/0056 , A61K31/195
摘要： There is disclosed a solid fast dispersing dosage form of a pharmaceutical composition suitable for oral administration comprising: a therapeutic agent which comprises one or more compound thyroid hormone or hormones; from about 80 % to about 99.9 % of disintegrating agent by mass; from about 0.01 % to about 10 % of flavouring agent by mass; and from about 0.1 % to about 5 % mass of lubricating agent by mass; which has utility in the treatment of disorders associated with the improvement of the thyroid hormone function in animals including human beings.
摘要翻译：公开了适用于口服给药的药物组合物的固体快速分散剂型，其包含：包含一种或多种化合物甲状腺激素或激素的治疗剂; 约80％至约99.9％的崩解剂; 约0.01％至约10％的调味剂; 和约0.1质量％至约5质量％的润滑剂; 其可用于治疗与包括人在内的动物的甲状腺激素功能改善相关的病症。

3. 发明申请

WO2012072977A8 FORMULATIONS COMPRISING METHYLTHIONINIUM CHLORIDE 审中-公开
标题翻译：包含甲基氯化铵的配方
公开(公告)号：WO2012072977A8
公开(公告)日：2012-09-20
申请号：PCT/GB2011001662
申请日：2011-11-30
申请人： WISTA LAB LTD , KHAN KARRAR AHMAD
发明人： KHAN KARRAR AHMAD
IPC分类号： A61K9/14 , A61K9/20 , A61K31/5415 , A61P25/28
CPC分类号： A61K31/5415 , A61K9/1652 , A61K9/20 , A61K9/2054 , A61K9/2095 , A61K9/4866 , C07D279/18
摘要： Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods.
摘要翻译：甲基硫堇（MTC）的固体剂型还包含至少一种适于直接压制的稀释剂。 MTC以基本上纯且稳定的多晶型形式存在。固体剂型可优选通过直接压制方法制备。

4. 发明申请

WO2012072977A3 FORMULATIONS COMPRISING METHYLTHIONIUM CHLORIDE 审中-公开
标题翻译：包含甲基氯化铝的配方
公开(公告)号：WO2012072977A3
公开(公告)日：2012-08-16
申请号：PCT/GB2011001662
申请日：2011-11-30
申请人： WISTA LAB LTD , KHAN KARRAR AHMAD
发明人： KHAN KARRAR AHMAD
IPC分类号： A61K9/14 , A61K9/20 , A61K31/5415 , A61P25/28
CPC分类号： A61K31/5415 , A61K9/1652 , A61K9/20 , A61K9/2054 , A61K9/2095 , A61K9/4866 , C07D279/18
摘要： Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods.
摘要翻译：甲基硫堇（MTC）的固体剂型还包含至少一种适于直接压制的稀释剂。 MTC以基本上纯且稳定的多晶型形式存在。固体剂型可优选通过直接压制方法制备。

5. 发明申请

WO2007107787A3 LIQUID AND SOLID DOSAGE FORMULATIONS CONTAINING DATE FRUIT (PHOENIX DACTYLIFERA) 审中-公开
标题翻译：含有水果的液体和固体剂量配方（PHOENIX DACTYLIFERA）
公开(公告)号：WO2007107787A3
公开(公告)日：2008-05-15
申请号：PCT/GB2007050124
申请日：2007-03-15
申请人： KHAN KARRAR AHMAD
发明人： KHAN KARRAR AHMAD
IPC分类号： A61K9/20 , A23L9/20 , A61K31/19 , A61K47/46
CPC分类号： A61K9/0095 , A23L19/09 , A23L33/105 , A23L33/15 , A23L33/16 , A23L33/40 , A61K9/0056 , A61K9/2068 , A61K31/19 , A61K47/46
摘要： Oral liquid and solid dosage formulations comprise a homogeneous dispersion of date material in a finely divided form. The formulation may be of nutritional and/or therapeutic value. Alternatively, the processed dates in the liquid and solid form may function purely as an excipient, in particular as an agent capable of improving the palatability of a pharmaceutically active substance with an unpleasant taste. The liquid formulation may be prepared by dispersing stoned, but otherwise whole date material in water, and subjecting the dispersion to homogenisation. The solid dose formulation preferably takes the form of granules, a tablet or a lozenge, and is preferably prepared by a process that involves the formation of a homogeneous dispersion of the date material in water, mixing of the date dispersion with some or all of the further ingredients of the formulation, and drying to remove excess water.
摘要翻译：口服液体和固体剂量制剂包含细分形式的日期材料的均匀分散体。制剂可具有营养和/或治疗价值。或者，液体和固体形式的加工日期可以纯粹作为赋形剂，特别是作为能够改善具有不愉快味道的药物活性物质的适口性的试剂。液体制剂可以通过将石头，但其他全部日期材料分散在水中并使分散体均化来制备。固体剂量制剂优选采用颗粒剂，片剂或锭剂的形式，并且优选通过涉及在水中形成日期物质的均匀分散体的方法制备，所述方法是将日期分散体与部分或全部制剂的其他成分，并干燥除去多余的水分。

6. 发明申请

WO2007107787A2 LIQUID AND SOLID DOSAGE FORMULATIONS CONTAINING DATES (PHOENIX DACTYLIFERA) 审中-公开
标题翻译：液体和固体剂量配方（PHOENIX DACTYLIFERA）
公开(公告)号：WO2007107787A2
公开(公告)日：2007-09-27
申请号：PCT/GB2007/050124
申请日：2007-03-15
申请人： KHAN, Karrar Ahmad
发明人： KHAN, Karrar Ahmad
IPC分类号： A23L9/20
CPC分类号： A61K9/0095 , A23L19/09 , A23L33/105 , A23L33/15 , A23L33/16 , A23L33/40 , A61K9/0056 , A61K9/2068 , A61K31/19 , A61K47/46
摘要： Oral liquid and solid dosage formulations comprise a homogeneous dispersion of date material in a finely divided form. The formulation may be of nutritional and/or therapeutic value. Alternatively, the processed dates in the liquid and solid form may function purely as an excipient, in particular as an agent capable of improving the palatability of a pharmaceutically active substance with an unpleasant taste. The liquid formulation may be prepared by dispersing stoned, but otherwise whole date material in water, and subjecting the dispersion to homogenisation. The solid dose formulation preferably takes the form of granules, a tablet or a lozenge, and is preferably prepared by a process that involves the formation of a homogeneous dispersion of the date material in water, mixing of the date dispersion with some or all of the further ingredients of the formulation, and drying to remove excess water.
摘要翻译：口服液体和固体剂量制剂包含细分形式的日期材料的均匀分散体。制剂可具有营养和/或治疗价值。或者，液体和固体形式的加工日期可以纯粹作为赋形剂，特别是作为能够改善具有不愉快味道的药物活性物质的适口性的试剂。液体制剂可以通过将石头，但其他全部日期材料分散在水中并使分散体均化来制备。固体剂量制剂优选采用颗粒剂，片剂或锭剂的形式，并且优选通过涉及在水中形成日期物质的均匀分散体的方法制备，所述方法是将日期分散体与部分或全部制剂的其他成分，并干燥除去多余的水分。

7. 发明申请

WO1995020955A1 LIQUID PHARMACEUTICAL COMPOSITIONS COMPRISING THYROID HORMONES 审中-公开
标题翻译：含有甲醛激素的液体药物组合物
公开(公告)号：WO1995020955A1
公开(公告)日：1995-08-10
申请号：PCT/EP1995000323
申请日：1995-01-30
申请人： THE BOOTS COMPANY PLC , DICKINSON, Jeffrey , KHAN, Karrar, Ahmad , HAGUE, John, Neville , SMITH, Alan
发明人： THE BOOTS COMPANY PLC
IPC分类号： A61K31/195
CPC分类号： A61K31/195 , A61K9/006 , A61K47/10 , Y10S514/909
摘要： There is disclosed a liquid pharmaceutical composition comprising a therapeutic agent which comprises: one or more thyroid hormone or hormones; from about 40 % to about 96 % ethanol by volume; a pH adjusting agent so that the measured pH of the composition is from about 9 to about 12; and from about 4 % to about 50 % water by volume; which has utility in the treatment of disorders associated with an impairment of the thyroid hormone function in animals including human beings. The liquid composition may be delivered by a metered dosage delivery system such as an aerosol or pump-action spray.
摘要翻译：公开了包含治疗剂的液体药物组合物，其包含：一种或多种甲状腺激素或激素; 约40％至约96％乙醇; pH调节剂，使得组合物的测量pH为约9至约12; 和约4％至约50％的水; 其可用于治疗与包括人在内的动物的甲状腺激素功能受损相关的疾病。液体组合物可以通过计量剂量递送系统例如气溶胶或泵作用喷雾来递送。

8. 发明申请

WO2012107706A8 PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE 审中-公开
标题翻译：双酚钠金属盐及其使用
公开(公告)号：WO2012107706A8
公开(公告)日：2013-09-19
申请号：PCT/GB2011001221
申请日：2011-08-15
申请人： WISTA LAB LTD , MARSHALL COLIN , CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , SINCLAIR JAMES PETER , BADDELEY THOMAS CRAVEN , ISHAQ AHTSHAM , SIMPSON MICHAEL , WILLIAMSON CRAIG , WOOD BARRY ALAN , WISCHIK CLAUDE MICHEL , HARRINGTON CHARLES ROBERT , RICKARD JANET ELIZABETH , HORSLEY DAVID , LOH YIN SZE , KHAN KARRAR AHMAD
发明人： MARSHALL COLIN , CLUNAS SCOTT , STOREY JOHN MERVYN DAVID , SINCLAIR JAMES PETER , BADDELEY THOMAS CRAVEN , ISHAQ AHTSHAM , SIMPSON MICHAEL , WILLIAMSON CRAIG , WOOD BARRY ALAN , WISCHIK CLAUDE MICHEL , HARRINGTON CHARLES ROBERT , RICKARD JANET ELIZABETH , HORSLEY DAVID , LOH YIN SZE , KHAN KARRAR AHMAD
IPC分类号： C07D279/20 , A61K31/5415 , A61P25/00
CPC分类号： A61K31/5415 , A61K9/0053 , A61K9/2095 , A61K9/2893 , A61L2/0052 , C07C303/32 , C07C309/04 , C07C309/05 , C07C309/30 , C07C309/35 , C07D279/20
摘要： The invention relates to compounds of general formula (I): wherein: each of R1 and R9 is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; each of R7NA and R7NB is independently selected from: -H, C1-4alkyl, C2-4alkenyl, and halogenated C1-4alkyl; and wherein: each of RA and RB is independently selected from: C1-4alkyl, halogenated C1-4alkyl, and C6-10aryl; or RA and RB are linked to form a group selected from: C1-6 alkylene and C6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.
摘要翻译：本发明涉及通式（I）的化合物：其中：R 1和R 9各自独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R 3NA和R 3NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R7NA和R7NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; 并且其中：RA和RB各自独立地选自：C 1-4烷基，卤代C 1-4烷基和C 6-10芳基; 或RA和RB连接形成选自以下的基团：C 1-6亚烷基和C 6-10亚芳基; 和其药学上可接受的盐，其可用于治疗例如阿尔茨海默氏病。在其它方面，本发明还涉及3,7-二氨基-10H-吩噻嗪鎓盐的新配方。

9. 发明申请

WO2012107706A1 PHENOTHIAZINE DIAMINIUM SALTS AND THEIR USE 审中-公开
标题翻译：双酚钠金属盐及其使用
公开(公告)号：WO2012107706A1
公开(公告)日：2012-08-16
申请号：PCT/GB2011/001221
申请日：2011-08-15
申请人： WISTA LABORATORIES LTD. , MARSHALL, Colin , CLUNAS, Scott , STOREY, John, Mervyn, David , SINCLAIR, James, Peter , BADDELEY, Thomas, Craven , ISHAQ, Ahtsham , SIMPSON, Michael , WILLIAMSON, Craig , WOOD, Barry, Alan , WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David , LOH, Yin, Sze , KHAN, Karrar, Ahmad
发明人： MARSHALL, Colin , CLUNAS, Scott , STOREY, John, Mervyn, David , SINCLAIR, James, Peter , BADDELEY, Thomas, Craven , ISHAQ, Ahtsham , SIMPSON, Michael , WILLIAMSON, Craig , WOOD, Barry, Alan , WISCHIK, Claude, Michel , HARRINGTON, Charles, Robert , RICKARD, Janet, Elizabeth , HORSLEY, David , LOH, Yin, Sze , KHAN, Karrar, Ahmad
IPC分类号： C07D279/20 , A61K31/5415 , A61P25/00
CPC分类号： A61K31/5415 , A61K9/0053 , A61K9/2095 , A61K9/2893 , A61L2/0052 , C07C303/32 , C07C309/04 , C07C309/05 , C07C309/30 , C07C309/35 , C07D279/20 , Y02A50/393 , Y02A50/411
摘要： The invention relates to compounds of general formula (I): wherein: each of R 1 and R 9 is independently selected from: -H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R 3NA and R 3NB is independently selected from: -H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; each of R7NA and R7NB is independently selected from: -H, C 1-4 alkyl, C 2-4 alkenyl, and halogenated C 1-4 alkyl; and wherein: each of R A and R B is independently selected from: C 1-4 alkyl, halogenated C 1-4 alkyl, and C 6-10 aryl; or R A and R B are linked to form a group selected from: C 1-6 alkylene and C 6-10 arylene; and pharmaceutically acceptable salts thereof, which are useful in the treatment of, for example, Alzheimer's disease. In other aspects the invention also relates to novel formulations of 3,7-diamino-10H-phenothiazinium salts.
摘要翻译：本发明涉及通式（I）的化合物：其中：R 1和R 9各自独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R 3NA和R 3NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; R7NA和R7NB中的每一个独立地选自：-H，C 1-4烷基，C 2-4链烯基和卤代C 1-4烷基; 并且其中：RA和RB各自独立地选自：C 1-4烷基，卤代C 1-4烷基和C 6-10芳基; 或RA和RB连接形成选自以下的基团：C 1-6亚烷基和C 6-10亚芳基; 和其药学上可接受的盐，其可用于治疗例如阿尔茨海默氏病。在其它方面，本发明还涉及3,7-二氨基-10H-吩噻嗪鎓盐的新配方。

10. 发明申请

WO2012072977A2 COMPOUND FORMULATIONS 审中-公开
标题翻译：化合物制剂
公开(公告)号：WO2012072977A2
公开(公告)日：2012-06-07
申请号：PCT/GB2011/001662
申请日：2011-11-30
申请人： WISTA LABORATORIES LTD. , KHAN, Karrar, Ahmad
发明人： KHAN, Karrar, Ahmad
IPC分类号： A61K9/14 , A61K9/20 , A61K31/5415 , A61P25/28
CPC分类号： A61K31/5415 , A61K9/1652 , A61K9/20 , A61K9/2054 , A61K9/2095 , A61K9/4866 , C07D279/18
摘要： Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods.
摘要翻译：甲基硫堇（MTC）的固体剂型还包含至少一种适于直接压制的稀释剂。 MTC以基本上纯且稳定的多晶型形式存在。固体剂型可优选通过直接压制方法制备。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式